Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia

W. Connell, J. M. Andrews, S. Brown, M. Sparrow

Research output: Contribution to journalReview ArticleResearchpeer-review

11 Citations (Scopus)

Abstract

Anti-tumour necrosis factor (TNF) therapy is an effective but expensive option for treating inflammatory bowel disease (IBD). Its use is generally reserved for patients with severe refractory disease, often involving long-term administration. Anti-TNF therapy has the potential to be associated with various adverse effects, such as infection, malignancy and immunogenicity. Clinicians and patients should be familiar with these possibilities and adopt appropriate precautions prior to and during treatment to minimize risk. Guidelines have been developed for Australian prescribers intending to use anti-TNF therapy in IBD by a Working Party commissioned by IBD-Australia, a Special Interest Group affiliated with the Gastroenterology Society of Australia.

Original languageEnglish
Pages (from-to)139-149
Number of pages11
JournalInternal Medicine Journal
Volume40
Issue number2
DOIs
Publication statusPublished - 10 Feb 2010
Externally publishedYes

Keywords

  • Adalimumab
  • Anti TNF therapy
  • Crohn's disease
  • Guidelines
  • Infliximab
  • Ulcerative colitis

Cite this